Spotlight Asset Group, Inc. Relmada Therapeutics, Inc. Transaction History
Spotlight Asset Group, Inc.
- $140 Million
- Q2 2024
A detailed history of Spotlight Asset Group, Inc. transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Spotlight Asset Group, Inc. holds 20,000 shares of RLMD stock, worth $11,800. This represents 0.04% of its overall portfolio holdings.
Number of Shares
20,000
Previous 20,000
-0.0%
Holding current value
$11,800
Previous $93,000
35.48%
% of portfolio
0.04%
Previous 0.07%
Shares
4 transactions
Others Institutions Holding RLMD
# of Institutions
50Shares Held
5.82MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA1.21MShares$712,7640.0% of portfolio
-
Acadian Asset Management LLC Boston, MA619KShares$365,4920.0% of portfolio
-
Black Rock Inc. New York, NY573KShares$338,2550.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA495KShares$292,1360.03% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD397KShares$233,9430.04% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $16.9M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...